Correction to: Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor (Invest New Drugs (2013) 31:1265–1274 (10.1007/s10637-012-9910-y))

Tetsuhide Ito; Takuji Okusaka; Toshirou Nishida; Kenji Yamao; Hisato Igarashi; Chigusa Morizane; Shunsuke Kondo; Nobumasa Mizuno; Kazuo Hara; Akira Sawaki; Satoshi Hashigaki; Nobuyuki Kimura; Mami Murakami; Emiko Ohki; Richard C. Chao; Masayuki Imamura

doi:10.1007/s10637-019-00757-9

Correction to: Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor (Invest New Drugs (2013) 31:1265–1274 (10.1007/s10637-012-9910-y))

Tetsuhide Ito, Takuji Okusaka, Toshirou Nishida, Kenji Yamao, Hisato Igarashi, Chigusa Morizane, Shunsuke Kondo, Nobumasa Mizuno, Kazuo Hara, Akira Sawaki, Satoshi Hashigaki, Nobuyuki Kimura, Mami Murakami, Emiko Ohki, Richard C. Chao, Masayuki Imamura

第１・消化器内科

研究成果: ジャーナルへの寄稿 › コメント/討論 › 査読

抄録

In the original publication of this article, the license subtype should be CC BYand not CC BY-NC. The original article has been corrected.

本文言語	英語
ページ（範囲）	591
ページ数	1
ジャーナル	Investigational New Drugs
巻	37
号	3
DOI	https://doi.org/10.1007/s10637-019-00757-9
出版ステータス	出版済み - 06-2019

All Science Journal Classification (ASJC) codes

腫瘍学
薬理学
薬理学（医学）

文献へのアクセス

10.1007/s10637-019-00757-9

他のファイルとリンク

フィンガープリント

「Correction to: Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor (Invest New Drugs (2013) 31:1265–1274 (10.1007/s10637-012-9910-y))」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル

Ito, T., Okusaka, T., Nishida, T., Yamao, K., Igarashi, H., Morizane, C., Kondo, S., Mizuno, N., Hara, K., Sawaki, A., Hashigaki, S., Kimura, N., Murakami, M., Ohki, E., Chao, R. C., & Imamura, M. (2019). Correction to: Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor (Invest New Drugs (2013) 31:1265–1274 (10.1007/s10637-012-9910-y)). Investigational New Drugs, 37(3), 591. https://doi.org/10.1007/s10637-019-00757-9

@article{758aea758ff64e26b58b2f57f8493c0d,

title = "Correction to: Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor (Invest New Drugs (2013) 31:1265–1274 (10.1007/s10637-012-9910-y))",

abstract = "In the original publication of this article, the license subtype should be CC BYand not CC BY-NC. The original article has been corrected.",

author = "Tetsuhide Ito and Takuji Okusaka and Toshirou Nishida and Kenji Yamao and Hisato Igarashi and Chigusa Morizane and Shunsuke Kondo and Nobumasa Mizuno and Kazuo Hara and Akira Sawaki and Satoshi Hashigaki and Nobuyuki Kimura and Mami Murakami and Emiko Ohki and Chao, {Richard C.} and Masayuki Imamura",

note = "Publisher Copyright: {\textcopyright} Springer Science+Business Media, LLC, part of Springer Nature 2019.",

year = "2019",

month = jun,

doi = "10.1007/s10637-019-00757-9",

language = "English",

volume = "37",

pages = "591",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Springer",

number = "3",

}

Ito, T, Okusaka, T, Nishida, T, Yamao, K, Igarashi, H, Morizane, C, Kondo, S, Mizuno, N, Hara, K, Sawaki, A, Hashigaki, S, Kimura, N, Murakami, M, Ohki, E, Chao, RC & Imamura, M 2019, 'Correction to: Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor (Invest New Drugs (2013) 31:1265–1274 (10.1007/s10637-012-9910-y))', Investigational New Drugs, vol. 37, no. 3, pp. 591. https://doi.org/10.1007/s10637-019-00757-9

Correction to: Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor (Invest New Drugs (2013) 31:1265–1274 (10.1007/s10637-012-9910-y)). / Ito, Tetsuhide; Okusaka, Takuji; Nishida, Toshirou その他.
In: Investigational New Drugs, Vol. 37, No. 3, 06.2019, p. 591.

研究成果: ジャーナルへの寄稿 › コメント/討論 › 査読

TY - JOUR

T1 - Correction to

T2 - Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor (Invest New Drugs (2013) 31:1265–1274 (10.1007/s10637-012-9910-y))

AU - Ito, Tetsuhide

AU - Okusaka, Takuji

AU - Nishida, Toshirou

AU - Yamao, Kenji

AU - Igarashi, Hisato

AU - Morizane, Chigusa

AU - Kondo, Shunsuke

AU - Mizuno, Nobumasa

AU - Hara, Kazuo

AU - Sawaki, Akira

AU - Hashigaki, Satoshi

AU - Kimura, Nobuyuki

AU - Murakami, Mami

AU - Ohki, Emiko

AU - Chao, Richard C.

AU - Imamura, Masayuki

PY - 2019/6

Y1 - 2019/6

N2 - In the original publication of this article, the license subtype should be CC BYand not CC BY-NC. The original article has been corrected.

AB - In the original publication of this article, the license subtype should be CC BYand not CC BY-NC. The original article has been corrected.

UR - http://www.scopus.com/inward/record.url?scp=85064035327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064035327&partnerID=8YFLogxK

U2 - 10.1007/s10637-019-00757-9

DO - 10.1007/s10637-019-00757-9

M3 - Comment/debate

C2 - 30903344

AN - SCOPUS:85064035327

SN - 0167-6997

VL - 37

SP - 591

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 3

ER -

Ito T, Okusaka T, Nishida T, Yamao K, Igarashi H, Morizane C その他. Correction to: Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor (Invest New Drugs (2013) 31:1265–1274 (10.1007/s10637-012-9910-y)). Investigational New Drugs. 2019 6月;37(3):591. doi: 10.1007/s10637-019-00757-9